BetterLife Pharma Inc (CSE:BETR) (OTCQB:BETRF) announced Thursday that it has entered into an agreement with List Biological Laboratories Inc for the manufacture of its proprietary interferon alpha 2b for the treatment of coronavirus (COVID-19.)
"Following our recent merger, we are proud to be continuing the development of Altum Pharmaceutical’s proprietary interferon alpha 2b inhalation for treatment of COVID-19,” said BetterLife's CEO Dr Ahmad Doroudian in a statement.
“We look forward to working with List Labs to bring this treatment to patients as quickly as possible as we prepare for our imminent trials in Australia.”
READ: BetterLife Pharma says special meeting of Altum shareholders has “overwhelming” voted to approve the planned merger
Under the terms of the agreement, List Labs will provide manufacturing services from its state-of-the-art biological development and cGMP manufacturing facility in Campbell, California.
Dr Doroudian added: "We are pleased to be partnering with List Labs in the manufacturing of our proprietary interferon alpha 2b. We believe our novel engineered interferon alpha 2b derived from our proprietary master cell bank offers important advantages that allow for a quick scale-up of manufacturing, especially in terms of logistics and cost of goods, which should enable us to meet potentially large demand (subject to regulatory clearance) once our treatment is ready for distribution. List Labs with its state-of-the-art manufacturing plant and agile team is an ideal partner to help realize our vision."
Dr Stacy Burns-Guydish, president of List Labs, called Altum Pharmaceutical’s interferon alpha 2b (AP-003) a “transformative therapeutic” for the treatment of COVID-19.
“List Lab’s expertise, quality, and flexibility in protein purification, process development, scale-up and cGMP manufacturing make us uniquely qualified to fulfill the contract development and manufacturing role for such an innovative product,” she said. “It is an honor to join in the fight against one of the greatest challenges of this decade.”
In other news, BetterLife said that it is not aware of any material, undisclosed corporate developments and has no material change to report at this time. Trading in the company’s shares on the OTCQB will resume after the Financial Industry Regulatory Authority has reviewed BetterLife’s recently submitted Form 211.
Contact the author: email@example.com
Follow him on Twitter @PatrickMGraham